
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
by Lynn Marie Morski, MD, JD
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇵🇪PE · Mental Health#196500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 ~2x weekly·201 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇵🇪100% - Active Followers
Loyal subscribers who consistently listen
200 to 1.2K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Choosing the Right Ketamine Clinic for You with Katie Fassbinder, MD
Jun 11, 2026
Unknown duration
The Future of Psychedelic Medicine with Ismail Lourido Ali, JD
May 28, 2026
Unknown duration
Psychedelics and Neurodiversity with Dr. WaiFung Tsang, DClinPsy
Apr 30, 2026
43m 31s
Spravato: The Accessible Psychedelic Medicine with Amy Della Rocca, PMHNP
Apr 9, 2026
42m 56s
Low-Dose Ketamine for Chronic Pain: A Biopsychosocial Approach with Michelle Weiner, DO, MPH
Mar 19, 2026
37m 33s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/11/26 | ![]() Choosing the Right Ketamine Clinic for You with Katie Fassbinder, MD | In this episode of the Psychedelic Medicine Podcast, Katie Fassbinder, MD joins to explore how to choose the right ketamine clinic. Dr. Fassbinder is the Faculty Medical Lead for ketamine-assisted psychotherapy training at Elemental Psychedelics and a practicing psychiatrist based in Wisconsin with over 20 years of experience. She also directs mental health and KAP programming at Promega and has worked extensively in public-sector mental health systems. In this conversation, Dr. Fassbinder explores how patients can make informed decisions when choosing a ketamine clinic, emphasizing that safety, therapeutic support, and personal fit should guide the process. She discusses the differences between medical ketamine treatment and ketamine-assisted psychotherapy, highlighting how factors such as trauma history, treatment goals, medical complexity, and access to integration support can influence the most appropriate model of care. The conversation also examines the strengths and limitations of various routes of administration, including IV, intramuscular, sublingual, and at-home ketamine programs. Throughout, Dr. Fassbinder stresses the importance of preparation, integration, set and setting, and finding a treatment environment that feels safe and supportive, noting that ketamine's benefits are often maximized when paired with meaningful therapeutic relationships and ongoing psychological support. In this episode, you'll hear: Key factors to consider when evaluating the safety of a ketamine clinic How medical and psychological needs influence the type of ketamine treatment that may be most appropriate The differences between ketamine-assisted psychotherapy and more medically oriented ketamine treatment models How IV, intramuscular, sublingual, and at-home ketamine approaches compare Why set, setting, preparation, and integration are critical components of successful treatment Who may be a good candidate for at-home ketamine programs and what risks to consider The distinction between psycholytic and psychedelic ketamine dosing and how each supports different therapeutic goals Resources and community-based options for psychedelic integration when ongoing therapy is not available Quotes: "[Ketamine] is one of those medicines that's very much a shape shifting medicine and it can meet people for different types of concerns or goals at different levels and different routes. So it's so good we have such a breadth of options—and very complicated if you're a patient trying to figure out where to begin." [7:55] "Those challenging psychedelic experiences, when well integrated, typically provide even more benefit for the person than the sort of bliss journeys that we all hope everybody gets to have, you know? So having a challenging journey, if well supported and integrated, is also a gift that's very potent for somebody that's really ready to do that work." [21:52] "Ego dissolution or that sort of loss of concept of self can be extremely liberating for some people. For others, coming back from that can be very discombobulating and even traumatic. So this really comes down to patient selection and helping people make a safe choice for what they're looking to do in their recovery and also what they're bringing in as risk factors for helping choose that safe dose range." [31:15] "While we don't have clarity about cognitive impacts of ketamine in the long run, it seems like when done therapeutically in pulses it's pro-cognitive. … But when done daily, what we've seen in recreational ketamine use—or misuse—is that it does have some cognitive impairment that's perhaps difficult to reverse." [42:58] "The dose of ketamine has so much to do with the preparation of your system more than the number of milligrams. … If you've done the at home course and you're not getting the sustained benefit or you're not journeying, it might be that that's a cue that you need more support for your actual sessions." [45:01] "Psychedelics and ketamine included, create a nonspecific amplification of everything. Everything feels bigger. And part of meeting with the ketamine provider is for them to really assess: Is this a good time in your life? Do you have the outside support, the inner resourcing to do this work safely?" [47:09] Links: Elemental Psychedelics website Elemental Psychedelics on LinkedIn Promega website Healing Maps website Fireside Project website ACER Integration website Journey Clinical website Usona Institute website "Psilocybin vs. Ketamine Training: Which is Right For Your Practice?" blog by Shannon Hughes and Dori Lewis Previous episode: Fireside Project: The World's First Psychedelic Hotline with Joshua White and Hanifa Nayo Washington Psychedelic Medicine Association Porangui | — | ||||||
| 5/28/26 | ![]() The Future of Psychedelic Medicine with Ismail Lourido Ali, JD | In the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the drug policy reform movement for over a decade, informed by half a lifetime of diverse personal experience with psychedelics and other substances. In this conversation, Ismail explores the rapidly evolving landscape of psychedelic medicine, reflecting on the field's major milestones, challenges, and future possibilities. He discusses how public perception has shifted over the past decade, the role of state-level psychedelic reforms, and the tensions created by commercialization, overhype, and competing regulatory models. Much of the discussion focuses on the recent federal executive order related to psychedelic research and drug development, including what it may mean for FDA approval timelines, right-to-try access, rescheduling, and public health standards. Throughout, Ismail emphasizes that psychedelics are not a "silver bullet," but tools that require strong systems of care, thoughtful policy, and community support to be integrated responsibly into healthcare and society. In this episode, you'll hear: How public attitudes toward psychedelics have shifted over the past decade Major milestones that expanded psychedelic policy reform beyond federal drug approval The promises and pitfalls of increased visibility, commercialization, and hype in the psychedelic field What the recent federal executive order on psychedelics actually does and does not do An explanation of right-to-try laws, FDA approval pathways, and the complexities of rescheduling psychedelic medicines Why maintaining rigorous evidentiary standards is essential for the long-term credibility of psychedelic medicine MAPS' vision for the future of psychedelic access, including regulated adult use, professional education, and community safety infrastructure How psychedelic policy reform could evolve to include broader systems of mental health care, crisis response, and social healing Quotes: "[Federal funding for psychedelic research] will only be so effective unless there is a massive reinvestment in mental health, harm reduction, and social services that actually ground—and one could say integrate—this medicine into like the continuum of care and the fabric of community that people are actually in." [25:07] "Even though those of us in the psychedelic advocacy field do want to see drugs like MDMA and others be approved by the FDA for medical use in these controlled clinical settings… At the same time, we don't want medical access to be accelerated so much that it's at the expense of public health or consumer protection or an evidentiary standard that other drugs are being held to." [37:59] "Medical professionals are not just prescribing things because they're approved. Many of them want to look at the evidence themselves. They want to look at the clinical trials. They want to understand 'is this the right choice for my patient?' But you can only know if [psychedelics] are being held to a comparable standard." [39:31] "What's MAPS' vision for ten years from now or 40 years from now for that matter? I like to think of it as lots of on ramps and lots of off ramps. It's that people who are seeking access to psychedelics for any beneficial purpose—for their own treatment or healing, for their own spiritual growth, for their personal development, for their for improving of their relationships with their loved ones or with nature or with spirituality, whatever that cosmology is that they hold—that they have safe, responsible methods of doing so." [44:47] Links: Ismail on Instagram Psychedelic Medicine Association Porangui | — | ||||||
| 4/30/26 | ![]() Psychedelics and Neurodiversity with Dr. WaiFung Tsang, DClinPsy✨ | psychedelicsneurodiversity+4 | Dr. WaiFung Tsang | OnayaHeroic Hearts Project+1 | Hong Kong | psychedelicsneurodiversity+5 | — | 43m 31s | |
| 4/9/26 | ![]() Spravato: The Accessible Psychedelic Medicine with Amy Della Rocca, PMHNP✨ | psychedelic medicineSpravato+3 | Amy Della Rocca | SpravatoMarpa+2 | New York | Spravatoesketamine+4 | — | 42m 56s | |
| 3/19/26 | ![]() Low-Dose Ketamine for Chronic Pain: A Biopsychosocial Approach with Michelle Weiner, DO, MPH✨ | low-dose ketaminechronic pain+4 | Michelle Weiner, DO, MPH | Neuropain Health | — | ketamine-assisted therapychronic pain treatment+3 | — | 37m 33s | |
| 3/4/26 | ![]() Ayahuasca for PTSD with Dr. Simon Ruffell MBChB, MRCPsych, PhD✨ | ayahuascaPTSD+5 | Dr. Simon Ruffell | OnayaUniversity of Exeter+2 | AmazonShipibo | ayahuascaPTSD+8 | — | 47m 29s | |
| 2/19/26 | ![]() Impacts of Social Inequality on Psychedelic Healing with Sean Viña, PhD✨ | social inequalitypsychedelic healing+4 | Sean M. Viña | Indiana University | — | psychedelicsmental health+7 | — | 39m 04s | |
| 2/4/26 | ![]() Psychedelics and Religion with Hunt Priest, MDiv✨ | psychedelicsreligion+4 | Hunt Priest | LigareJohns Hopkins+2 | — | psychedelicsChristianity+5 | — | 45m 51s | |
| 1/22/26 | ![]() Encore Episode: How Psychedelics Affect the Brain with Manesh Girn, PhD✨ | psychedelicsbrain action+4 | Manesh Girn | EntheoTech BioscienceTrends in Cognitive Sciences+1 | McGill University | psychedelicsbrain+4 | — | 38m 02s | |
| 1/8/26 | ![]() Which Psychedelic for Which Condition? with Will Van Derveer, MD✨ | psychedelic medicinemental health conditions+3 | Will Van Derveer, MD | MAPSShambala+1 | — | psychedelicsmental health+8 | — | 45m 08s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/17/25 | ![]() Psychedelics for the Menopause Transition with Alicia Bigelow, ND✨ | psychedelic medicinemenopause transition+4 | Alicia Bigelow, NDAlicia Bigelow | Rise Up JourneysMenomorphosis | Portland, OR | psychedelicsmenopause+6 | — | 35m 26s | |
| 12/4/25 | ![]() Psychedelics as Catalysts for Human Agency with Matthew W. Johnson, PhD✨ | psychedelicshuman agency+4 | Matthew W. Johnson, PhD | — | — | psilocybinmystical experience+5 | — | 44m 27s | |
| 11/20/25 | ![]() Psychedelics and Movement with Dmitry Repin, PhD | In this episode, Dmitry Repin, PhD joins to discuss the intersection of bodily movement and psychedelics. Dr. Repin is the co-founder of the Institute for Psychedelic Research at Tel Aviv University, holds a PhD in cognitive neuroscience, and is the producer and creative force behind the Everything Else Matters documentary. In this conversation, Dr. Repin explores how psychedelics may influence movement, proprioception, and motor learning, drawing from his background in neuroscience and his transformative experiences with dance practices like Gaga. He describes his team's innovative clinical study pairing psilocybin with guided movement training to investigate whether altered states can open temporary windows of enhanced plasticity for learning new movement patterns. Throughout the discussion, Dr. Repin reflects on why so many people feel inhibited in their bodies, how psychedelics might soften these constraints, and what traditional movement-based ceremonies can teach modern clinical research about embodiment, healing, and the relationship between perception and action. In this episode, you'll hear: How dance and Gaga inspired Dr. Repin's scientific interest in movement during psychedelic states Kinesiophobia and why many people experience fear, shame, or inhibition around movement Why Dr. Repin chose psilocybin for his study on psychedelics and movement How Dr. Repin's study measures movement changes using optical tracking and multi-dimensional metrics What makes Gaga movement practices unique compared to other approaches to dance and movement The structure of the psilocybin-plus-movement protocol developed at Tel Aviv University How psychedelics may temporarily enhance motor learning through shifts in proprioception and neuroplasticity What ritual and communal dance contexts reveal about the embodied dimensions of psychedelic experiences Quotes: "If we understand those [neurological] mechanisms, we can try to influence certain situations where people have deficits related to movement." [4:47] "For example, when I go to a dance training session [after a recent psychedelic experience], I find that I actually internalize movement patterns much faster than I do otherwise—and it's noticeable to my dance teacher." [8:56] "Part of the hypothesis that we have is that certain qualities or dimensions of movement might be affected more or less by psychedelics than others and that potentially, will give us some insights into the specific brain mechanisms because certain different types of movement sometimes require different circuits to engage in different parts of the body." [19:47] "Some initial wisdom, some anecdotes, or some best practices that have been developed within those non-clinical settings may be very useful to inform clinical—and maybe other—areas that use psychedelics." [27:03] Links: Everything Else Matters documentary The Institute for Psychedelic Research at Tel Aviv University Dr. Repin on LinkedIn Dr. Repin on X Psychedelic Medicine Association Porangui | — | ||||||
| 11/13/25 | ![]() Psychedelic Medicine: Updates from the field with Lynn Marie Morski, JD, MD | In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible. Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation. In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48] Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui | — | ||||||
| 10/29/25 | ![]() Psilocybin-Assisted Group Therapy for Depression with Matthew Hicks, ND, MS | In this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks is a research Investigator at the National University of Natural Medicine as well as a Naturopathic doctor and licensed psilocybin facilitator at Synaptic Institute. In this conversation, Dr. Hicks shares findings from one of the first studies investigating psilocybin-assisted group therapy for depression, conducted in Oregon's new legal psilocybin framework. He explains how the high cost and labor-intensive nature of psychedelic therapy inspired him to explore a group model that could make treatment more financially accessible while preserving - and even enhancing - its therapeutic potential. Dr. Hicks describes the structure of the study and discusses how initial participant hesitancy about group work transformed into deep connection and shared healing. He also highlights the study's significant reductions in depression scores, improvements across quality-of-life measures, and the potential for group-based approaches to pave the way toward insurance reimbursement and broader access to psychedelic care. In this episode, you'll hear: Why affordability and accessibility were central motivations for developing a group-based psilocybin protocol The benefits and challenges of conducting psilocybin sessions in a shared group setting How Dr. Hicks' study balanced inclusion of low-income participants with safety and stability criteria The details of the group treatment structure for Dr. Hicks' study Why Dr. Hicks believes group formats may be inherently therapeutic in addition to their economic efficiency Dr. Hicks's vision for future efficacy and cost-effectiveness studies that could enable insurance coverage Quotes: "In terms of the group dynamic, almost everyone in the intake process was very reluctant. They were trepidatious. They were a little worried about the group part of it. And almost everybody at the end of it, when we did the follow ups at the group, was amazing. People made friends. They felt really supported. They felt really seen by the process of hearing other people's journeys and the growth that they went through—and seeing some other examples of transformation was really powerful and was really encouraging to me." [10:29] "So [there are] really positive aspects to doing this in a group format that's not just economic—it's not just cheaper to do this in group, it actually has therapeutic benefits that you miss out on when you only do this one on one." [11:12] "That was always my question in the follow up sessions: 'did your participation in this study change the way you engaged in psychotherapy? Did it change the relationship with your therapist?' And a lot of people reported that it did. They felt they were able to open up and engage more deeply, be more introspective. And it did, in many cases, not all, improve their psychotherapy outcomes as well." [18:24] "Some people reported that hearing someone else in the group crying for a bit really opened up something in them and they almost felt grateful for that. This other person is having a meaningful experience over there, and that's something they wouldn't have gotten on their own if they hadn't heard that person crying." [22:45] Links: Dr. Hicks on LinkedIn Synaptic Institute website Dr. Hicks' research at Synaptic Institute National University of Natural Medicine website Psychedelic Medicine Association Porangui | — | ||||||
| 10/2/25 | ![]() Microdosing Psilocybin: Truth vs Hype with Rotem Petranker, PhD | In this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker is the co-founder of the Psychedelic Studies Research Program at the University of Toronto and the Canadian Centre for Psychedelic Science. He recently ran the world's largest randomized controlled trial on the effectiveness of microdosing psilocybin on Major Depressive Disorder. In this conversation, Dr. Petranker shares insights from running the world's largest randomized controlled trial on psilocybin microdosing for major depressive disorder. He explains the origins of microdosing research, from early anecdotes and surveys to his team's carefully designed clinical study comparing psilocybin to placebo across different environments. While participants in both groups reported significant improvements, the findings point to the powerful role of expectancy and placebo effects, alongside nuanced signals of cognitive shifts on measures like dysfunctional attitudes. Dr. Petranker emphasizes the importance of rigorous methodology, open science, and transparency in psychedelic research, while also acknowledging the stories of participants whose lives were positively impacted by study participation itself. In this episode, you'll hear: What early microdosing research suggested, and its limitations in anecdotal and survey-based designs Why psilocybin was chosen over LSD for the study design What motivates people to try microdosing a psychedelic Key results from Dr. Petranker's study, including reports of both positive and adverse events How placebo effects—and simply being part of a trial—can powerfully shape outcomes Reflections on how psychedelics may work by increasing connectedness Quotes: "There's no real rigorous definition [of microdosing]. People say, 'oh, I'm just going to microdose some mushrooms,' and then they often take a random amount. I think what people mean is 'I'm going to take an amount that will not knock me out, won't cause serious hallucinations,' but they still use an amount that they often feel. Now, this is in contrast to what people in the [academic] literature define it as, which is more like a sub-perceptual dose, a sub-hallucinogenic dose." [2:17] "If you microdose and go to work, just to sit under the flickering lights for eight hours in your cubicle versus, say, if you're going to microdose and then go on a walk, or do art, or do as you wish because it's the weekend, you're going to have very different impacts on your anxiety." [15:26] "[In our study] there were three other self-report measures of depression. There is only a significant difference on one of them, where people who were microdosing were doing better. And that was on the dysfunctional attitude scale, which measures more cognitive assumptions about life." [26:2] "people who microdose—regardless of why they microdose—they more or less all said that they got to what they wanted through an increased sense of meaning." [35:05] Links: Psychedelic Studies Research Program at the University of Toronto Canadian Centre for Psychedelic Science website Canadian Centre for Psychedelic Science on X Canadian Centre for Psychedelic Science on Instagram Previous episode: Microdosing and the Placebo Effect with Balazs Szigeti, PhD Previous episode: James Fadiman answers your Microdosing Questions! Psychedelic Medicine Association Porangui | — | ||||||
| 9/17/25 | ![]() Encore Episode: Exploring Endogenous DMT with Rick Strassman, MD | In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook. His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S. In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don't know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use. In this episode you'll hear: The overlap between psychedelic experiences and meditation techniques The relationship between fear, self-awareness, and difficult DMT experiences The placebo effect and psychedelic research Dr. Strassman's thoughts on non-hallucinogenic psychedelics DMT as a possible treatment for strokes to prevent damage and speed recovery Effects of microdosing in animals and humans Quotes: "I think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. … Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug." [9:45] "You could still speculate that to the extent that non-drug states resemble those brought on by giving DMT… that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research." [24:16] "If psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT." [27:42] "If you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube." [32:27] Links: Dr. Strassman's website The Psychedelic Handbook by Dr. Strassman DMT: The Spirit Molecule by Dr. Strassman DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman Dr. Strassman on FacebookPrevious episode: Exploring DMT Entities with Matthew Johnson, PhD Psychedelic Medicine Association Porangui | — | ||||||
| 9/4/25 | ![]() Psychedelics for Stroke Healing with Steven Zeiler, MD, PhD | In this episode Steven Zeiler, MD, PhD joins to discuss the promise of psychedelics for stroke healing. Dr. Zeiler is an associate professor and physician at Johns Hopkins School of Medicine specializing in cerebrovascular disease, including acute stroke therapy, prevention, and recovery. He is a lead investigator for a Rose Hill Life Sciences research trial, conducted in partnership with Johns Hopkins University, exploring the use of psilocybin-assisted therapy to enhance motor function in patients with neurological injuries. In this conversation, Dr. Zeiler explains that after a stroke, there is a natural but time-limited critical period during which the brain is highly plastic and capable of repairing motor function. His research, inspired by work on psychedelics reopening critical learning windows, shows in animal models that a single high dose of psychedelics combined with intensive rehabilitation can restore lost motor abilities even after recovery has plateaued. Throughout, Dr. Zeiler emphasizes that psilocybin itself doesn't heal the brain directly but creates a window of heightened neuroplasticity that, when paired with targeted therapy, may dramatically improve recovery outcomes for stroke survivors. In this episode, you'll hear: What happens to patients during a stroke The critical period of stroke recovery and how psychedelics may reopen this opportunity Why conducting a safety and tolerability study of psilocybin for stroke patients is crucial What forms of deficits and recoveries Dr. Zeiler's study will measure Dr. Zeiler's speculations on what integrating psychedelic treatments into stroke medicine could look like The importance of specialized interventions that take advantage of the critical recovery period Quotes: "What has been a little forgotten about in a lot of stroke management situations is helping the person get over the deficits with which the stroke has left them. And if you can't move an arm, you can't move a leg, that's a big deal. And we are not quite as good at addressing some of those problems." [5:11] "[The potential of psychedelics for stroke recovery] is probably less about addressing the injury itself and more about helping the remaining parts of the brain turn on to address what's lost." [7:36] "We're not suggesting that the psychedelic itself has some sort of magical property that would just repair the brain, but it primes the situation to allow that input that we then provide over the next many days, many weeks, to affect a recovery." [13:31] "Imagine something as complicated as the brain going through a repair mechanism: could you imagine one molecule acting on one receptor being able to affect a recovery? I couldn't imagine that—it's too complicated a thing. And so having something like a mechanism of action that is acting through multiple pathways, I think has to be the case if we're going to affect something as complicated as brain repair." [17:30] Links: Dr. Zeiler on LinkedIn Super Room for Enriched Neurological Repair at Green Spring (SENRG) PHATHOM (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability)-Stroke Project Psychedelic Medicine Association Porangui | — | ||||||
| 8/20/25 | ![]() Long-Term Psychedelic Integration with J. Ashley T. Booth, LCSW, MS | In this episode J. Ashley T. Booth, LCSW, MS joins to discuss the importance of long-term psychedelic integration. Ashley is a Los Angeles-based psychedelic therapist, IFS practitioner, and author of Quieting the Storm Within: An Illustrated Introduction to Your Parts Through Internal Family Systems and Beyond. With a background in research, education, and clinical work—including serving as a co-investigator on the MAPS MDMA trials—she specializes in helping clients integrate psychedelic experiences through compassionate parts work and Self-led healing. In this conversation, Ashley explores the nuances of psychedelic integration, discussing how this process can be supported through ongoing self-audits, somatic practices, and Internal Family Systems (IFS) work. She highlights the need to slow down, focus on one insight at a time, and anchor felt experiences into the body so they become lived behaviors rather than fleeting memories. The discussion also addresses challenges such as insufficient integration, psychedelic narcissism, and the pressure to "fix" oneself. In closing, Ashley stresses that even years after a journey, integration is possible if one revisits experiences with intention, and she underscores the central role of supportive communities in sustaining lasting transformation In this episode, you'll hear: What things are important to focus on in long-term integration How someone can discern when their integration process has been sufficient to pursue a subsequent psychedelic journey An overview of the internal family systems model of the psyche The downsides of insufficient integration Developing deeper relationships with the parts of one's psyche through IFS Why it's never too late to integrate psychedelic experiences from one's past What to do when integration seems to come into conflict with feeling well adjusted to society's expectations Quotes: "What I encourage clients to do is to take notes on everything that felt important and then separate them out into: 'I'm going to just focus on this one thing for like a month, and then maybe next month will be that second piece of it.' And so you're really allowing yourself to make particular practices and focus on one thing at a time." [6:21] "So whatever wound we're dealing with in our bodies, whether it's an extreme sort of big T trauma or little T trauma… there's a slowness that needs to happen. And so if there's parts of us that want to speed up that process, we need to be curious about that and see if there are ways that we can tend to that before the next journey." [13:59] "I think that part of the longer term questions are not just how we change our life but what kind of meaning are we making of our lives and how are we sitting more comfortably in that meaning in a way that is serving us and empowering us?" [25:52] Links: Ashley's website IFS and Beyond on Instagram IFS and Beyond website Quieting the Storm Within: An Illustrated Introduction to Your Parts Through Internal Family Systems and Beyond by J. Ashley T. Booth Aware Project: Southern California Psychedelic Society website Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Psychedelic Medicine Association Porangui | — | ||||||
| 8/7/25 | ![]() Combining Ketamine Therapy with Other Modalities with Genesee Herzberg, PsyD | In this episode, Dr. Genesee Herzberg joins to discuss the ways ketamine therapy can be combined with other healing modalities. Dr. Herzberg is a clinical psychologist and co-founder and director of Sage Integrative Health, an integrative psychedelic therapy clinic and training center in the SF Bay Area. She worked as a therapist on the MDMA for PTSD clinical trials and co-edited the book Integral Psychedelic Therapy. In this conversation, Dr. Herzberg explains how somatic therapy, touch therapy, bodywork, and movement support trauma processing. She also highlights the benefits of combining ketamine with acupuncture, craniosacral therapy, and functional medicine—including nutritional and hormonal assessments—to address physiological contributors to mental health. In closing, Dr. Herzberg emphasizes trauma-informed, team-based, and individualized approach to psychedelic healing, where ketamine acts as a bridge between psychological, somatic, and biomedical treatments. In this episode, you'll hear: How somatic therapy is used within ketamine therapy sessions How ketamine helps quiet the default mode network to support therapeutic processing Ensuring safety during physical and movement-based therapies The importance of establishing boundaries and explicit consent for therapeutic work that involves touch Dr. Herzberg's first hand experience of the reciprocal benefits of combining acupuncture and ketamine therapy Using functional medicine and nutrition therapy to support the therapeutic process with ketamine Quotes: "I see ketamine, especially at lower psychoanalytic doses… as a support in turning down the volume on emotional and physical pain, which can then help us to better experience them. So I think of it as a sort of 're-associative'." [4:08] "Another aspect of the healing potential of therapy in general has to do with a therapeutic relationship: developing this sense that there's someone who cares about you, who's there to support you, who's going to be right there with you as you're dropping into your scariest and darkest places. And touch is one of the best ways to communicate that." [13:53] "Acupuncture can help the nervous system to relax and help the system to open to the ketamine such that we are able to more fully receive the benefits of the medicine and feel the effects of it." [25:07] Links: Sage Integrative Health website Dr. Herzberg on LinkedIn Sage Integrative Health on LinkedIn Sage Integrative Health on Instagram Sage Integrative Health on Facebook Integral Psychedelic Therapy: The Non-Ordinary Art of Psychospiritual Healing edited by Jason A. Butler, Genesee Herzberg, and Richard Louis Miller Previous episode: Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc Psychedelic Medicine Association Porangui | — | ||||||
| 7/24/25 | ![]() Art Therapy for Psychedelic Preparation and Integration with Charmaine Husum, RCAT | In this episode, Charmaine Husum joins to discuss how art therapy can be a powerful tool for psychedelic preparation and integration. Charmaine is a Registered Art Therapist, Somatic Counsellor and Kundalini Yoga Teacher with over 12 years of experience supporting psychedelic preparation and integration. Her courses train professionals globally using specifically developed protocols in trauma-informed, harm-reduction practices, with her book, Psychedelics and Art Therapy: A Trauma-Informed Manual for Somatic Self Expression (Routledge, 2025), endorsed by numerous experts in the field including Stan and Brigitte Grof. In this discussion, Charmaine distinguishes between art as therapy and art therapy, emphasizing that the latter involves clinically informed, trauma-sensitive practices that externalize inner experiences to support healing. She outlines structured protocols used before and after psychedelic experiences, including creating visual representations of inner strength, setting intentions, and integrating experiences through multi-phase art exercises. Throughout, Charmaine emphasizes choice, embodiment, and the historical roots of art in altered states, offering a rich alternative for those seeking non-verbal, experiential ways to work through trauma and transformation. In this episode, you'll hear: The types of art and materials employed in art therapy How art therapy can be employed to support preparation for a psychedelic experience Using art therapy for grounding and restabilization following an intense psychedelic journey Judith Herman's three stage model of healing trauma Why drawing a self portrait with one's non-dominant hand could be therapeutic Pursuing shadow work in art therapy Working with a client's perfectionism in art therapy Quotes: "[Art therapy] is not about making art, actually. It's about being in the present moment, about moving materials, about allowing for often a cathartic release, and giving expression to what we often don't have words for." [3:14] "Art therapy isn't just about making the art, it's about processing the art afterwards." [7:48] "Art therapy is very helpful when we're trying to express something that's ineffable—something without words—which is… at the heart of psychedelics. There's often no words to describe what our experience has been. And so using creativity can be a real help there." [29:06] Links: Centre of the HeArt website Centre of the HeArt on Instagram Centre of the HeArt on Facebook Charmaine on LinkedIn Charmaine's book: Psychedelics and Art Therapy: A Trauma-Informed Manual for Somatic Self Expression Psychedelic Medicine Association Porangui | — | ||||||
| 7/9/25 | ![]() Is Psilocybin Safe for Me? with Seth Mehr, MD | In this episode, Seth Mehr, MD joins to share his expertise on safety planning prior to a patient undergoing psilocybin therapy. After a 20 year career as an Emergency Medicine physician, Seth founded Cascade Psychedelic Medicine in 2021, treating clients with depression, anxiety and PTSD with psychedelic ketamine therapy. He also serves as the Health & Safety Director and a state licensed psilocybin facilitator at the Innertrek service center in Portland, Oregon. In this conversation, Dr. Mehr outlines key risk categories for psilocybin therapy: medical conditions, medication interactions, and mental health history. He emphasizes the importance of individualized safety planning over binary yes/no decisions. Dr. Mehr discusses specific considerations such as cardiovascular issues, diabetes, serotonergic medications, substance use disorders, suicidal ideation, and family history of psychosis. The conversation also covers strategies for mitigating risk, including delaying treatment, contingency plans, improving support systems, and ensuring informed consent. Throughout, Dr. Mehr stresses a collaborative, nuanced approach that balances potential benefits with careful preparation and personalized care. In this episode, you'll hear: Stories from Dr. Mehr's practice of helping patients with different conditions and histories ensure safe psilocybin experiences Interactions between GLP-1 agonists and psilocybin How Dr. Mehr works with patients who have family histories of psychosis Harm reduction practices which leverage other psychedelics or non-psychedelic interventions to help prepare a client for a psilocybin session Why insulin dependent diabetes can be a contraindication for psychedelic therapy What medication combinations can increase the risk of serotonin toxicity with psilocybin Supporting clients experiencing spiritual emergency following psilocybin therapy Safety considerations when working with clients who have a history of seizures The importance of having contingency plans if medical emergencies arise during psilocybin therapy The intricacies of providing fully informed consent for psychedelic therapy Quotes: "There is some evidence now that taking a single serotonergic agent—say, taking Lexapro—and no other medications that increase the risk of serotonin toxicity seems safe where I am not at this point recommending that people stop, skip, or taper a single SSRI in preparation for a psilocybin session due to safety." [12:20] "One of the difficulties with making these decisions or speaking with some confidence or authority on the matter is that the clinical trials that have been done largely exclude people with lots of conditions—family history and specifically first degree relatives with history of psychosis and bipolar disorder… So we have anecdotal evidence, we have population based surveys to go by. And so when I talk to clients about this, I speak from a place of humility." [27:30] "I always emphasize to clients that while we're talking about a specific safety issue like serotonin toxicity, we don't want to trade that for psychological instability and crisis and declare success because we've helped somebody taper off of a medication that seems less safe and now they aren't sleeping, they're agitated, they're depression is worse, their suicidality is worse. So we have to take a holistic approach to this and consider the totality of what's happening with that client." [36:45] "There are so many different components to trying to set somebody up for success rather than a yes/no, black and white approach [to psilocybin therapy]." [48:44] Links: Cascade Psychedelic Medicine website InnerTrek website Managing Medical Risk In Patients Seeking Psilocybin Therapy CME/CE Course Psychedelic Medicine Association Porangui | — | ||||||
| 6/25/25 | ![]() Addressing Racial Trauma through Psychedelic Therapy with Monnica T. Williams, PhD, ABPP | In this episode, Monnica T. Williams, PhD, ABPP joins to discuss how psychedelics may help alleviate mental health impacts of racial trauma. Dr. Williams is a licensed clinical psychologist and professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair in Mental Health Disparities. In this conversation, Dr. Williams begins by highlighting the daily stress and trauma experienced by people of color, likening it to PTSD. She discusses a survey her team conducted which revealed that many people of color use psychedelics to manage racial trauma, showing significant reductions in stress, depression, and anxiety. Additionally, Dr. Williams emphasizes the importance of a safe environment and culturally competent therapists. In closing, she discusses ongoing research at this intersection and the need for more funding and awareness in this field. In this episode, you'll hear: How racial trauma manifests as conditions like PTSD, depression, and anxiety The importance of an intersectional perspective Current treatments for mental health struggles stemming from racial trauma Results from Dr. Williams' research into psychedelic use amongst people of color The importance of safe and supportive settings for psychedelic experiences How shared life experiences between a therapist and client can strength the therapeutic alliance and improve outcomes Why bias training is particularly important in the context of psychedelic therapy Quotes: "People of color who live in these white dominated Western contexts are continually bombarded by subtle —and not so subtle—messages about their worth, about their standing in society, about their intelligence, their character, on and on and on and on. And so really the daily onslaught just wears and wears away at people, and the stress of that can actually become traumatizing." [1:49] "People heal from trauma when someone witnesses their pain, right? When people can compassionately witness your pain and join in it with you—this is the basis behind all therapeutic approaches for trauma treatment." [10:13] "We saw [from our survey study] that many, many people of color are using psychedelics to manage racism, often very quietly. But it seems for many people to be quite effective and quite helpful." [11:53] "We looked at some separate psychedelics where we had enough people who described a specific one like psilocybin or LSD or peyote in some cases. And so we were able to look at those psychedelics separately and we didn't actually find a difference. It didn't seem to matter which psychedelic it was. It seemed that they were all, more or less equally effective." [15:20] Links: Dr. Williams' website Dr. Williams on X Dr. Williams on Instagram Dr. Williams on LinkedIn Dr. Williams' study "Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada" Behavioral Wellness Clinic - Connecticut Behavioural Wellness Clinic - Ottawa Masters Program in Psychedelics and Consciousness Studies at University of Ottawa Psychedelic Medicine Association Porangui | — | ||||||
| 6/12/25 | ![]() Understanding Psychedelics and Neuroplasticity with Robin Carhart-Harris, PhD | In this episode, Robin Carhart-Harris, PhD joins to elucidate the intersection of psychedelics and neuroplasticity. Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine's '100 Next' – a list of 100 rising stars shaping the future. Dr. Carhart-Harris begins by discussing the impact of psychedelics on neuroplasticity and mental health. He explains neuroplasticity as the brain's ability to change, emphasizing its role in mood disorders and substance use and describes how stress atrophies the brain, leading to mental illness. Dr. Carhart-Harris differentiates between neuroplasticity and neurogenesis, noting that while neurogenesis is limited in adults, neuroplasticity can be influenced by psychedelics like ketamine, psilocybin, and MDMA. In closing, he also discusses the entropic brain hypothesis, suggesting that increased brain entropy leads to richer subjective experiences. In this episode, you'll hear: The relationship between neuroplasticity and "canalization" Why homeostatic neuroplasticity may promote mental wellbeing Differences between ketamine, MDMA, and serotonergic psychedelics in terms of neuroplasticity The details of the entropic brain hypothesis Psychedelics' effect on the default mode network The frontiers of research into psychedelics and neuroplasticity Quotes: "So changeability is what plasticity is. And neuroplasticity—that's the ability of the brain to change. Okay, and how is neuroplasticity related to mood disorders like depression and anxiety or substance use disorder or something like that? Well, that's a great question cause we don't have it entirely nailed down. But one of the most reliable findings in biological psychiatry is that stress atrophies the brain." [2:47] "The main thing with ketamine is that the window of increased plasticity is brief… That makes sense because that reflects how ketamine seems to work therapeutically—that it provides relief somewhat short-term, unless it is twinned with, say, psychotherapy or you do repeat administration and get someone out of the rut they were in." [22:15] "We've seen in people with depression, brain networks can become quite segregated from each other—they are ordinarily, they're quite functionally separate and distinct—but that modularity might be a bit elevated in depression. But what we've seen with psilocybin therapy is that separateness between systems, that segregated quality of organization of brain networks, brain systems actually decreases after psilocybin therapy for depression. I'll put it another way: the brain looks more globally interconnected after psilocybin therapy for depression and the magnitude of that… correlates with improvements." [39:19] Links: Carhart-Harris Lab website Dr. Carhart-Harris on X Dr. Carhart-Harris' 2025 article: "Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models" Dr. Carhart-Harris' 2012 article: "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin" Dr. Carhart-Harris' 2010 article with Karl Friston: "The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas" Psychedelic Medicine Association Porangui | — | ||||||
| 5/28/25 | ![]() Myths and Misconceptions About Psilocybin with Dori Lewis, LPC | In this episode, Dori Lewis, MA, MEd, LPC-S discusses the common myths and misconceptions surrounding psilocybin for healing. Dori is a psychotherapist, co-founder of Elemental Psychedelics, and owner of Reflective Healing in Fort Collins, CO, who specializes in psychedelic-assisted therapy, blending transpersonal psychology with spiritual practices. With experience facilitating ketamine sessions and training clinicians, she advocates for ethical standards in psychedelic medicine while championing a feminine-centered approach to facilitator training. The first myth that Dori addresses in this conversation is the idea that it is the psilocybin mushroom itself that does all the healing work. Contrary to this common misconception, Dori suggests that it is the client's own initiative working in tandem with the mushroom that really spurs healing. She also emphasizes that there are not any set protocols for how often psilocybin should be taken for healing, instead suggesting that clients should be guided to attune to their own internal intuition to determine when a psilocybin journey may be particularly helpful. Another misconception Dori addresses is that healing with psilocybin can occur without causing deep transformations in one's identity or shifts in one's worldview. She suggests facilitators must be very transparent about these possible impacts to best prepare clients for these kinds of major changes that psilocybin can catalyze. In closing, Dori reiterates that clients should be supported and prepared to encounter intense emotional experiences with psilocybin, as some of the most difficult psychedelic journeys can actually be the most healing. In this episode, you'll hear: The biggest myths and misconceptions Dori encounters working with clients in her practice The importance of a relational understanding of psychedelic healing The specific types of trauma where psilocybin may be a particularly effective healing modality The training for psilocybin facilitators in Colorado under the Natural Medicines Program and the importance of scope of practice Why some people's mental health gets worse before it gets better following a psilocybin experience What can cause lack of response to psilocybin therapy and how better preparation can often mitigate this Quotes: "Mushrooms are amazing and they can help us in our healing journey. But they are one tool in a mosaic of other tools that we can use to help ourselves heal and grow and change." [6:54] "I don't really know where this message came from—that mushrooms cure PTSD—but that is a huge myth. They can help—with certain types of trauma within the context of a healthy therapeutic relationship with a skilled provider, yes, at times when it is right. But ultimately the best medicine for trauma is going to be MDMA—and ketamine." [18:18] "It is the responsibility of providers and facilitators to inform clients of the realistic expectations they should have for their [psychedelic] journeys—and that is also an ethical need and something that facilitators need to consider through an ethical lens." [25:20] "There's a lot to be said about the unique ways that mushrooms express through our bodies and through our minds and through our hearts that give us information about where we are at and where we need to work or continue to work in order to access the healing we so desire." [37:34] Links: Dori on LinkedIn Elemental Psychedelics on LinkedIn Elemental Psychedelics website Previous episode: Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA Previous episode: The Challenging Psychedelic Experiences Project with Jules Evans Previous episode: The Dangers of "Ayahuasca Told Me…" with Jerónimo Mazarrasa Psychedelic Medicine Association Porangui | — | ||||||
Showing 25 of 204
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.

























